Contraindicated in personal/family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2)
Li, Y., Liu, W., Li, L
Its peptides are sold research use only, and in 2023 BPC-157 was formally placed by the FDA into an interim category of bulk substances flagged for significant safety risks, citing immunogenicity, impurities, and a lack of human safety data
Yang Y, Chen L, Zhang Y, Fu W, Liu D, Jiang T (2025) Research on the effects of GLP-1 receptor agonists in treating cognitive dysfunction and gait disorders in elderly patients with diabetes
Anti-TSHR antibodies differ from anti-TPO and anti-Tg antibodies in many respects (localization of the antigen, class, action, duration of increased levels, and prevalence of the antibody), which are indicated in Table 1